Table 7 Characteristics of patients according to the expression level of FADD
From: Proteomic analysis predicts anti-angiogenic resistance in recurred glioblastoma
Characteristics | High expression (n = 42) | Low expression (n = 51) | P-value |
|---|---|---|---|
Age, years | 53.4 ± 2.0 | 54.5 ± 2.0 | 0.59 |
Male sex | 19 (45%) | 29 (57%) | 0.002 |
Pre-bevacizumab KPS score | 55.9 ± 2.3 | 60.85 ± 2.1 | 0.85 |
Molecular type | |||
 IDH wild type | 20 (48%) | 26 (51%) | 0.02 |
 MGMT promoter status (methylated/unmethylated/NA) | 17/7/18 | 16/12/23 |  |
Surgical resection type | |||
 Partial resection | 19 (45%) | 20 (39%) | 0.56 |
 Gross total resection | 23 (55%) | 31 (61%) |  |
Drug treatment | |||
 Temozolomide + bevacizumab | 32 (76%) | 32 (76%) 42 (82%) |  |
 Monotherapy | 10 (24%) | 9 (18%) |  |
 Temozolomide duration, days | 250.2 ± 35.2 | 216.1 ± 24.1 | 0.19 |
 .Avastin dose, mg/kg | 594.1 ± 16.0 | 588.5 ± 19.8 | 0.074 |
Treatment outcomes | |||
 Overall survival, days | 972.5 ± 136.2 | 764 ± 68.56 |  < 0.001 |
 Progression-free survival, days | 499.9 ± 100.1 | 393.6 ± 46.6 |  < 0.001 |
 Initial tumor size, mm3 | 41753 ± 6764 | 41138 ± 4151 | 0.008 |
 Recurred tumor size, mm3 | 30212 ± 5443 | 31958 ± 5661 | 0.41 |